Improving quality of life for patients with diabetes and chronic disease
Our research in prevention and management of chronic illness is key to improving lives. By translating new findings into care, we reduce the impact on individuals, their families and communities.
We study diabetes management, complications and interventions as well as innovative technologies. Our International Diabetes Center has conducted hundreds of diabetes-related studies. This includes participation in landmark studies such as Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and the Glycemia Reduction Approaches in Diabetes: A comparative Effectiveness Study (GRADE).
Our hypertension research program is also well established. We participated in several landmark multicenter trials funded by the National Heart, Lung, and Blood Institute. These trials examined blood pressure and heart outcomes. They include ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the Women’s Health Initiative, and ACCORD. We have also studied blood pressure outcomes, including methods to improve hypertension through telemonitoring and pharmacist support.
Demonstrating how technology can improve diabetes management
We developed and gathered consensus for the ambulatory glucose profile (AGP), the first continuous glucose monitoring (CGM) software to analyze and display glucose patterns. The American Diabetes Association, along with seven other diabetes organizations around the world, endorsed the value of the AGP. Learn more at the AGP website.
We showed use of real-time CGM improves the way people with type 2 diabetes use basal insulin to manage their condition. This data expands the number of people who could benefit from these devices, and points to a possible future in which CGMs are common in primary care clinics.
We studied whether an automated insulin dose guidance system can offer more effective ways to tailor doses of insulin and improve diabetes management.